# A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

> **NCT00918411** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 98 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Ramosetron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00918411
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918411, "A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00918411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*